中危前列腺癌淋巴结分期的诊断准确性及结局
该回顾性研究纳入8043例接受根治性前列腺切除加盆腔淋巴结清扫的中危前列腺癌患者,评估CT、MRI和PSMA-PET检测淋巴结浸润的诊断效能及肿瘤学结局。结果显示各模态敏感性均有限,PSMA-PET最高为13%,CT仅0.9%;PSMA-PET阴性者生化复发无生存和转移无生存显著更优。
要点
- 中危前列腺癌淋巴结浸润率为7.8%(624/8043)。
- PSMA-PET敏感性13%,MRI 8.3%,CT 0.9%,均有限。
- PSMA-PET阴性者生化复发无生存和转移无生存显著更优。
核心结论
- 所有评估的分期模态在中危前列腺癌中检测淋巴结浸润的敏感性均有限,包括PSMA-PET。
- 鉴于常规影像诊断效能差,此场景下或可省略此类检查。
- PSMA-PET可选择性考虑,因其提供中等敏感性和预后价值,但作用仍有限。
研究设计与样本
- 回顾性分析2015至2021年接受根治性前列腺切除加盆腔淋巴结清扫的中危前列腺癌患者。
- 排除接受新辅助激素治疗者。
- 共纳入8043例患者,评估CT、MRI和PSMA-PET检测淋巴结浸润的效果。
主要发现
- 8043例中624例(7.8%)存在淋巴结浸润。
- PSMA-PET组400例:真阳性6例,假阴性40例,假阳性14例,真阴性340例。
- CT组2079例:真阳性2例,假阴性228例,假阳性7例,真阴性1842例。
- MRI组148例:真阳性1例,假阴性11例,真阴性136例,无假阳性。
- 敏感性PSMA-PET最高(13%),其次MRI(8.3%)和CT(0.9%);阴性预测值MRI 92.5%、PSMA-PET 89.5%、CT 89%。
关键数值与推荐
- 敏感性:PSMA-PET 13%,MRI 8.3%,CT 0.9%。
- 阴性预测值:MRI 92.5%,PSMA-PET 89.5%,CT 89%。
- PSMA-PET阴性者生化复发无生存和转移无生存显著优于PSMA-PET可疑发现者。
临床怎么用
- 中危前列腺癌患者常规影像(CT/MRI)检测淋巴结浸润敏感性低,此场景下或可省略。
- PSMA-PET可选择性用于提供中等敏感性和预后信息,但作用有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the diagnostic performance of different staging modalities and oncological outcomes in patients with intermediate-risk (IR) prostate cancer (PCa) undergoing radical prostatectomy (RP) with pelvic lymph node dissection (PLND). PATIENTS AND METHODS: Patients with IR PCa who underwent RP and PLND between 2015 and 2021 were retrospectively analysed. Patients who had received neoadjuvant hormone therapy were excluded. The effectiveness of computed tomography (CT), magnetic resonance imaging (MRI), and prostate-specific membrane antigen-positron emission tomography (PSMA-PET) in detecting lymph node invasion (LNI) was assessed. Kaplan-Meier analysis was used to evaluate biochemical recurrence-free and metastasis-free survival. RESULTS: Among 8043 patients with IR PCa undergoing RP with PLND, 624 (7.8%) had LNI. PSMA-PET was performed in 400 patients: six true positives, 40 false negatives, 14 false positives, and 340 true negatives. CT was used in 2079 patients: two true positives, 228 false negatives, seven false positives, and 1842 true negatives. MRI was performed in 148 patients: one true positive, 11 false negatives, and 136 true negatives, with no false positives. Sensitivity was highest for PSMA-PET (13%), followed by MRI (8.3%) and CT (0.9%). Negative predictive values were 92.5% for MRI, 89.5% for PSMA-PET, and 89% for CT. Patients with negative PSMA-PET findings had significantly better biochemical recurrence-free and metastasis-free survival than those with suspicious findings on PSMA-PET. CONCLUSIONS: All evaluated staging modalities demonstrated limited sensitivity in detecting LNI in patients with IR PCa, including PSMA-PET. Given the poor diagnostic performance of conventional imaging, such methods may be omitted in this setting. PSMA-PET may still be considered selectively, as it provides modest sensitivity and prognostic value, although its role remains limited.
引用
- Kniep C, Maurer T, Hartwieg BF, et al. Diagnostic accuracy and outcomes of lymph node staging in intermediate-risk prostate cancer. BJU Int. 2026. PMID: 41577442. doi:10.1111/bju.70155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。